General MedicationsINTRAMUSCULARGeneric
ARIPIPRAZOLE
ARIPIPRAZOLE
Standard Dose
300MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ARIPIPRAZOLE is listed in Drugs@FDA under application 216608 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ARIPIPRAZOLE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 300MG/VIAL Sponsor MYLAN Submission history Latest submission status date: 2024-12-03 00:00:00.
Structured Monograph
Clinical summary
Approval overview ARIPIPRAZOLE is listed in Drugs@FDA under application 216608 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ARIPIPRAZOLE Form and strength FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 300MG/VIAL Sponsor MYLAN Submission history Latest submission status date: 2024-12-03 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.